These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11167663)

  • 1. Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure.
    Brynne L; McNay JL; Schaefer HG; Swedberg K; Wiltse CG; Karlsson MO
    Br J Clin Pharmacol; 2001 Jan; 51(1):35-43. PubMed ID: 11167663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators.
    Swedberg K; Bergh CH; Dickstein K; McNay J; Steinberg M
    J Am Coll Cardiol; 2000 Feb; 35(2):398-404. PubMed ID: 10676687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure.
    Dickstein K; Manhenke C; Aarsland T; McNay J; Wiltse C; Wright T
    Int J Cardiol; 2000 Sep; 75(2-3):167-76; discussion 176-7. PubMed ID: 11077130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure.
    Swedberg K; Bristow MR; Cohn JN; Dargie H; Straub M; Wiltse C; Wright TJ;
    Circulation; 2002 Apr; 105(15):1797-803. PubMed ID: 11956122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Dickstein K; Manhenke C; Aarsland T; Køpp U; McNay J; Wiltse C
    Am J Cardiol; 1999 Jun; 83(12):1638-44. PubMed ID: 10392868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: application to moxonidine.
    Trocóniz IF; de Alwis DP; Tillmann C; Callies S; Mitchell M; Schaefer HG
    Clin Pharmacol Ther; 2000 Jul; 68(1):18-27. PubMed ID: 10945312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
    Mao Z; Wheeler JJ; Townsend R; Gao Y; Kshirsagar S; Keirns JJ
    J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):541-62. PubMed ID: 21786177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine.
    Mobini R; Fu M; Jansson PA; Bergh CH; Scharin Täng M; Waagstein F; Andersson B
    Clin Sci (Lond); 2006 Mar; 110(3):329-36. PubMed ID: 16209659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure.
    Põder P; Eha J; Sundberg S; Antila S; Heinpalu M; Loogna I; Planken U; Rantanen S; Lehtonen L
    Int J Clin Pharmacol Ther; 2003 Aug; 41(8):365-73. PubMed ID: 12940594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patients.
    Kirch W; Hutt HJ; Plänitz V
    J Clin Pharmacol; 1990 Dec; 30(12):1088-95. PubMed ID: 2273081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial.
    Böhm M; Robertson M; Borer J; Ford I; Komajda M; Mahfoud F; Ewen S; Swedberg K; Tavazzi L
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON).
    Cohn JN; Pfeffer MA; Rouleau J; Sharpe N; Swedberg K; Straub M; Wiltse C; Wright TJ;
    Eur J Heart Fail; 2003 Oct; 5(5):659-67. PubMed ID: 14607206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The I1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress.
    Wenzel RR; Mitchell A; Siffert W; Bührmann S; Philipp T; Schäfers RF
    Br J Clin Pharmacol; 2004 May; 57(5):545-51. PubMed ID: 15089806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of digitoxin versus trichlormethiazide/amiloride in congestive heart failure NYHA class II/III and sinus rhythm.
    Huonker M; Sorichter S; Schmidt-Trucksäss A; Irmer M; Staiger J; Keul J
    Cardiovasc Drugs Ther; 1999 May; 13(3):233-41. PubMed ID: 10439886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian variation in blood pressure and heart rate in nonhypertensive congestive heart failure.
    Giles TD; Roffidal L; Quiroz A; Sander G; Tresznewsky O
    J Cardiovasc Pharmacol; 1996 Dec; 28(6):733-40. PubMed ID: 8961069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
    Ollivier JP; Christen MO
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model.
    Van Kerckhoven R; van Veen TA; Boomsma F; Saxena PR; Schoemaker RG
    Eur J Pharmacol; 2000 May; 397(1):113-20. PubMed ID: 10844105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form.
    Schaefer HG; Heinig R; Ahr G; Adelmann H; Tetzloff W; Kuhlmann J
    Eur J Clin Pharmacol; 1997; 51(6):473-80. PubMed ID: 9112062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives.
    Wenzel RR; Spieker L; Qui S; Shaw S; Lüscher TF; Noll G
    Hypertension; 1998 Dec; 32(6):1022-7. PubMed ID: 9856967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.